Anti-Inflammatory and Cancer Antibodies make out 65% of the Innovator Biologics Market in 2025
BARCELONA, Spain I March 10, 2026 I La Merie Publishing announced the publication of the biologics market report for the…
Pipeline of MUC16-Targeted Immunotherapy
MUC16: old target revisited with new technologies – a pipeline review STUTTGART, Germany I November 10, 2025 I La Merie…
Pipeline of CDH6-Targeted Immunotherapy
CDH6: clinical PoC of lead anti-CDH6 ADC boosts pipeline – a pipeline review STUTTGART, Germany I November 08, 2025 I…
Pipeline of MUC1-Targeted Immunotherapy
MUC1: an old target accessed with new technologies leading to first signs of clinical activity – a pipeline review STUTTGART,…
Pipeline of Claudin 18.2-Targeted Immunotherapy
Claudin 18.2: a clinically validated target and plenty of improvement options with new drug modalities – a pipeline review STUTTGART,…
Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies
PD-L1 and 4-1BB (CD137): promising immuno-oncology therapy combination to overcome on-target-off-tumor toxicity – a pipeline review STUTTGART, Germany I September…
Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy
CD47 and SIRPα: next generation inhibitors to show clinical benefit – a pipeline review STUTTGART, Germany I September 23, 2025…
Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists
Complement C5: a commercially successful and clinically effective treatment of C5 mediated diseases – a pipeline review STUTTGART, Germany I…
Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors
IL-6 and IL-6R: hot targets for underexploited indications – a pipeline review STUTTGART, Germany I September 09, 2025 I La…
Pipeline of CD40 Agonists and CD40/L Antagonists
CD40 and CD40L: a versatile target as co-stimulator in cancer and for antagonism in autoimmune diseases – a pipeline review…